ScripVenture capital fundraising data show that $100m-plus mega-rounds continue to account for the vast majority of biopharmaceutical company VC financings, with overall investment in large rounds and indi
ScripThe positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp
ScripIt took four weeks, but the second quarter of 2022 finally has its first two biopharmaceutical initial public offerings in the US, launched by HilleVax, Inc. and Belite Bio late on 28 April. The o